Propanc Biopharma Inc. (PPCB)
PPCB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PPCB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001517681 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report." | 10-Q 2026-11-13 |
| Cash and burn | $832K cash; operating cash flow -$1.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,048,247 (2026-11-12); 13,364,244 a year earlier; 22,258,941 three years earlier. 1y figure adjusted for splits (1-for-250 overall); 3y figure adjusted for splits (1-for-500 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 3; latest 1-for-10 on 2026-10-26 | Source 2026-10-26 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-10-29 |
| Auditor | Salberg & Company, P.A., Boca Raton, Florida, United States | PCAOB Form AP 2026-09-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | Not filed | -$4.6M | -$1.6M | $832K | $201K | Needs four quarters | 10-K 2026-09-25 |
| Q3 2026 2026-03-31 | Not filed | -$6.4M | -$1.1M | $444K | $55K | Needs four quarters | 10-Q 2026-05-14 |
| Q2 2026 2025-12-31 | Not filed | -$3.1M | -$999K | $561K | $55K | Needs four quarters | 10-Q 2026-05-14 |
| Q1 2026 2025-09-30 | Not filed | -$4.8M | -$1.9M | $603K | $107K | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-06-30 | Not filed | -$4.1M | -$92K | $12K | $538K | Needs four quarters | 10-K 2026-09-25 |
| Q3 2025 2025-03-31 | Not filed | -$54.1M | -$96K | $51K | $439K | Needs four quarters | 10-Q 2026-05-14 |
| Q2 2025 2024-12-31 | Not filed | -$430K | $19K | $15K | $410K | Needs four quarters | 10-Q 2026-05-14 |
| Q1 2025 2024-09-30 | Not filed | -$354K | -$236K | $9K | $382K | Needs four quarters | 10-Q 2026-05-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-10-05 |
| Latest annual report | 10-K | 2026-09-25 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | PRE 14A | 2026-03-19 |
Source: SEC EDGAR submissions feed, 439 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.7% |
| 1 month | -52.9% |
| 3 months | -84.1% |
| Year to date | -98.6% |
| 1 year | -99.0% |
| From 52-week high | -99.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
| JUNS | Jupiter Neurosciences Inc. | $1.70 | -8.11% | $2.2M |
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier